TAG7 + PGRP-S gene therapy

TAG7 + PGRP-S gene therapy is a **gene-modified autologous tumor cell vaccine** in which a patient's own tumor cells are transfected ex vivo with genes encoding the innate immunity protein Tag7 (also known as PGRP-S or PGLYRP1), then irradiated and administered as a vaccine. The therapy aims to enhance immune system recognition and elimination of tumor cells, particularly in advanced malignant melanoma and renal cell carcinoma. Tag7/PGRP-S is known as a peptidoglycan recognition protein integral to the innate immune response, capable of binding bacterial peptidoglycan and exhibiting antimicrobial and immunomodulatory functions. When introduced into tumor cells, the modified cells may provoke an immune response against cancer through mediated activation of immune effector mechanisms. Phase I/II clinical trials have demonstrated feasibility, safety, and evidence of antitumor immunological activity, with stabilization or minor responses in a subset of patients. The mechanism differs from checkpoint inhibitors, focusing on active immune stimulation by modified tumor antigens rather than release from immune inhibition. Survival benefit is most notable in patients whose tumors exhibit low levels of immunosuppressive factors (e.g., TGF-β1, IL-10, VEGF).

Other names

tag7/PGRP-S gene-modified vaccinetag7/PGRP-S gene vaccineGMV